{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:10:18Z","timestamp":1780333818038,"version":"3.54.1"},"reference-count":76,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["2021\/41\/B\/NZ7\/03757"],"award-info":[{"award-number":["2021\/41\/B\/NZ7\/03757"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["B.SUB.24.340"],"award-info":[{"award-number":["B.SUB.24.340"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","award":["2021\/41\/B\/NZ7\/03757"],"award-info":[{"award-number":["2021\/41\/B\/NZ7\/03757"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","award":["B.SUB.24.340"],"award-info":[{"award-number":["B.SUB.24.340"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Animal preclinical experiments in pulmonary hypertension (PH) need to be conducted with detailed methodological rigor to improve their translational relevance. One of its crucial yet insufficiently studied aspects is animal body weight (BW). Thus, our study aimed to examine the influence of initial BW on the severity of PH development induced by monocrotaline (MCT) and the effectiveness of the reference combined therapy (ambrisentan and tadalafil given for 21 days). Male rats were divided into three weight Sets: Set I (200\u2013219 g); Set II (220\u2013239 g); and Set III (240\u2013259 g), after which, MCT-PH was induced. The measurements taken included in vivo echocardiographic evaluations, ex vivo functional experiments (on isolated right ventricle papillary muscles and pulmonary arteries), and histological and morphometric assessments. In all three Sets of animals, we noticed evidence of PH development. More pronounced changes confirming the severity of PH were observed in Set II compared to Sets I and III. The effectiveness of the reference therapy was also most evident in Set II, where the reversal of PH-related aggravations was best documented. We demonstrated that both the severity of MCT-induced PH in rats and the effectiveness of the reference combined therapy strongly depend on the animals\u2019 initial BW.<\/jats:p>","DOI":"10.3390\/ijms26188916","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:33:02Z","timestamp":1758007982000},"page":"8916","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Initial Body Weight as an Important Factor for Improving the Reliability and Translational Relevance of the Preclinical Monocrotaline-Induced Rat Pulmonary Hypertension Model"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-2226","authenticated-orcid":false,"given":"Patryk","family":"Remiszewski","sequence":"first","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2416-6039","authenticated-orcid":false,"given":"Piotr","family":"Ryszkiewicz","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-2656","authenticated-orcid":false,"given":"Marta","family":"Baranowska-Kuczko","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-2731","authenticated-orcid":false,"given":"Anna","family":"P\u0119dzi\u0144ska-Betiuk","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6894-0953","authenticated-orcid":false,"given":"Krzysztof","family":"Mi\u0144czuk","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7374-0999","authenticated-orcid":false,"given":"Monika","family":"Kloza","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-9391","authenticated-orcid":false,"given":"Jolanta","family":"Weresa","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Hutsch","sequence":"additional","affiliation":[{"name":"Department of Pathology and Veterinary Diagnostics, Institute of Veterinary Medicine, University of Life Sciences, 02-776 Warsaw, Poland"},{"name":"Veterinary Diagnostic Laboratory ALAB Bioscience, 00-739 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-8153","authenticated-orcid":false,"given":"Barbara","family":"Malinowska","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"H702","DOI":"10.1152\/ajpheart.00021.2022","article-title":"Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies","volume":"322","author":"Christou","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12931-024-02994-w","article-title":"Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: A systematic review of outcomes reported by population-based observational studies","volume":"25","author":"Reinders","year":"2024","journal-title":"Respir. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41569-024-01064-4","article-title":"Mechanisms and treatment of pulmonary arterial hypertension","volume":"22","author":"Ghofrani","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","volume":"64","author":"Chin","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bph.14866","article-title":"Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment","volume":"178","author":"Tello","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-2600(23)00264-3","article-title":"Treatment of pulmonary arterial hypertension: Recent progress and a look to the future","volume":"11","author":"Humbert","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.121.319971","article-title":"The latest in animal models of pulmonary hypertension and right ventricular failure","volume":"130","author":"Boucherat","year":"2022","journal-title":"Circ. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bph.15444","article-title":"Animal models of pulmonary hypertension: Getting to the heart of the problem","volume":"179","author":"Dignam","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ame2.12220","article-title":"Experimental animal models of pulmonary hypertension: Development and challenges","volume":"5","author":"Wu","year":"2022","journal-title":"Anim. Model. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","article-title":"The monocrotaline model of pulmonary hypertension in perspective","volume":"302","author":"Farkas","year":"2012","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fr\u00f6hlich, E. (2024). Animals in respiratory research. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052903"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.phrs.2017.08.003","article-title":"Animal models of pulmonary arterial hypertension: A systematic review and meta-analysis of data from 6126 animals","volume":"125","author":"Sztuka","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jasi\u0144ska-Stroschein, M. (2024). An updated review of experimental rodent models of pulmonary hypertension and left heart disease. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1308095"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure","volume":"297","author":"Stenmark","year":"2009","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10557-020-07109-3","article-title":"Toward better reproducibility in experimental research on new agents for pulmonary hypertension. An analysis of data from four hundred animal studies","volume":"35","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"173952","DOI":"10.1016\/j.ejphar.2021.173952","article-title":"Reporting experimental studies on animals\u2014The problems with translating of outcomes to clinical benefits. Methodological and statistical considerations: The example of pulmonary hypertension","volume":"897","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Errington, T.M. (2024). Building reproducible bridges to cross the \u201cvalley of death\u201d. J. Clin. Investig., 134.","DOI":"10.1172\/JCI177383"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.117.312579","article-title":"Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational research","volume":"122","author":"Provencher","year":"2018","journal-title":"Circ. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"H351","DOI":"10.1152\/ajpheart.00098.2024","article-title":"Sex-dependent remodeling of right ventricular function in a rat model of pulmonary arterial hypertension","volume":"327","author":"Kwan","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/bph.16277","article-title":"Pulmonary arterial hypertension: Sex matters","volume":"181","author":"Dignam","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/j.2040-4603.2020.tb00109.x","article-title":"Sex, gender, and sex hormones in pulmonary hypertension and right ventricular failure","volume":"10","author":"Hester","year":"2019","journal-title":"Compr. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4939-8597-5_18","article-title":"Pulmonary artery hypertension model in rats by monocrotaline administration","volume":"1816","author":"Sassi","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.chest.2017.10.007","article-title":"Fifty years of monocrotaline-induced pulmonary hypertension: What has it meant to the field?","volume":"152","author":"Hill","year":"2017","journal-title":"Chest"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Krstic, A.M., Jones, T.L.M., Power, A.S., and Ward, M.L. (2024). The monocrotaline rat model of right heart disease induced by pulmonary artery hypertension. Biomedicines, 12.","DOI":"10.3390\/biomedicines12091944"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pharep.2015.10.004","article-title":"Age-specific influences of chronic administration of the fatty acid amide hydrolase inhibitor URB597 on cardiovascular parameters and organ hypertrophy in DOCA-salt hypertensive rats","volume":"68","author":"Toczek","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Remiszewski, P., P\u0119dzi\u0144ska-Betiuk, A., Mi\u0144czuk, K., Schlicker, E., Klimek, J., Dzi\u0119cio\u0142, J., and Malinowska, B. (2022). Effects of the peripheral CB1 receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.965613"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sadowska, O., Baranowska-Kuczko, M., Gromotowicz-Pop\u0142awska, A., Biernacki, M., Kicman, A., Malinowska, B., Kasacka, I., Krzy\u017cewska, A., and Koz\u0142owska, H. (2020). Cannabidiol ameliorates monocrotaline-induced pulmonary hypertension in rats. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197077"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11906-016-0689-7","article-title":"Pulmonary arterial hypertension and the sex hormone paradox","volume":"18","author":"Foderaro","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"H496","DOI":"10.1152\/ajpheart.00549.2024","article-title":"Sexual dimorphism in right ventricular adaptation to pressure overload involves differential angiogenic response","volume":"328","author":"Seelemann","year":"2025","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"H1253","DOI":"10.1152\/ajpheart.00857.2013","article-title":"Sex differences in the pulmonary circulation: Implications for pulmonary hypertension","volume":"306","author":"Martin","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Frump, A.L., Albrecht, M., Yakubov, B., Breuils-Bonnet, S., Nadeau, V., Tremblay, E., Potus, F., Omura, J., Cook, T., and Fisher, A. (2021). 17\u03b2-Estradiol and estrogen receptor \u03b1 protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. J. Clin. Investig., 131.","DOI":"10.1172\/JCI129433"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Barbera","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12967-014-0314-y","article-title":"Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition","volume":"12","author":"Cavasin","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.116.237933","article-title":"Tryptophan hydroxylase 1 inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension","volume":"360","author":"Aiello","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/CIRCULATIONAHA.124.070693","article-title":"Exploring integrin \u03b15\u03b21 as a potential therapeutic target for pulmonary arterial hypertension: Insights from comprehensive multicenter preclinical studies","volume":"151","author":"Lemay","year":"2025","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/cvr\/cvae244","article-title":"C-C Motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator","volume":"121","author":"Tsuboya","year":"2025","journal-title":"Cardiovasc. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12931-022-02005-w","article-title":"CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension","volume":"23","author":"Kabwe","year":"2022","journal-title":"Respir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2045894020947283","DOI":"10.1177\/2045894020947283","article-title":"Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats","volume":"10","author":"Mamazhakypov","year":"2020","journal-title":"Pulm. Circ."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Souza, N.S.C., Barenco-Marins, T., Ferraz, A.P., Barbosa, R.A.Q., Maciel, L., Ponte, C.G., Seara, F.A.C., Olivares, E.L., and Nascimento, J.H.M. (2024). Low thyroid hormones level attenuates mitochondrial dysfunction and right ventricular failure in pulmonary hypertensive rats. Cardiovasc. Drugs Ther., ahead of print.","DOI":"10.1007\/s10557-024-07618-5"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1080\/13813455.2020.1769679","article-title":"Exercise training decreases oxidative stress in skeletal muscle of rats with pulmonary arterial hypertension","volume":"128","author":"Becker","year":"2022","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bcpt.13309","article-title":"Effects of inorganic nitrate in a rat model of monocrotaline-induced pulmonary arterial hypertension","volume":"126","author":"Malikova","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Videja, M., Vilskersts, R., Korzh, S., Cirule, H., Sevostjanovs, E., Dambrova, M., and Makrecka-Kuka, M. (2021). Microbiota-derived metabolite trimethylamine N-oxide protects mitochondrial energy metabolism and cardiac functionality in a rat model of right ventricle heart failure. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.622741"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ho\u0142da, M.K., Stachowicz, A., Suski, M., Wojtysiak, D., Sowi\u0144ska, N., Arent, Z., Palka, N., Podolec, P., and Kope\u0107, G. (2020). Myocardial proteomic profile in pulmonary arterial hypertension. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-71264-8"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12967-020-02440-7","article-title":"Changes in heart morphometric parameters over the course of a monocrotaline-induced pulmonary arterial hypertension rat model","volume":"18","author":"Szczepanek","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ho\u0142da, M.K., Ra\u017any, U., Sordyl, M., G\u00f3ralska, J., Kapusta, M., S\u0142owi\u0144ska-Solnica, K., Wojtysiak, D., Lis, G., Solnica, B., and Kope\u0107, G. (2024). Autophagy and ubiquitin-dependent proteolysis processes in left ventricular mass loss in pulmonary arterial hypertension. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-64950-4"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"121988","DOI":"10.1016\/j.lfs.2023.121988","article-title":"Therapeutic effects of hypoxia-preconditioned bone marrow-derived mesenchymal stromal cells and their extracellular vesicles in experimental pulmonary arterial hypertension","volume":"329","author":"Braga","year":"2023","journal-title":"Life Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Silva, A.F., Faria-Costa, G., Sousa-Nunes, F., Santos, M.F., Ferreira-Pinto, M.J., Duarte, D., Rodrigues, I., Tiago Guimar\u00e3es, J., Leite-Moreira, A., and Moreira-Gon\u00e7alves, D. (2019). Anti-remodeling effects of xanthohumol-fortified beer in pulmonary arterial hypertension mediated by ERK and AKT inhibition. Nutrients, 11.","DOI":"10.3390\/nu11030583"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jphs.2021.05.012","article-title":"Comparative analysis of age in monocrotaline-induced pulmonary hypertensive rats","volume":"147","author":"Kawade","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Cuijpers, I., Carai, P., Mendes-Ferreira, P., Simmonds, S.J., Mulder, P., Miranda-Silva, D., De Giorgio, D., Pokreisz, P., Heymans, S., and Jones, E.A.V. (2020). The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-72924-5"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Logantha, S., Yamanushi, T.T., Absi, M., Temple, I.P., Kabuto, H., Hirakawa, E., Quigley, G., Zhang, X., Gurney, A.M., and Hart, G. (2023). Remodelling and dysfunction of the sinus node in pulmonary arterial hypertension. Philos. Trans. R. Soc. Lond. B Biol. Sci., 378.","DOI":"10.1098\/rstb.2022.0178"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Han, J.C., Guild, S.J., Pham, T., Nisbet, L., Tran, K., Taberner, A.J., and Loiselle, D.S. (2017). Left-ventricular energetics in pulmonary arterial hypertension-induced right-ventricular hypertrophic failure. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.01115"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Absi, M., Eid, B.G., Ashton, N., Hart, G., and Gurney, A.M. (2019). Simvastatin causes pulmonary artery relaxation by blocking smooth muscle ROCK and calcium channels: Evidence for an endothelium-independent mechanism. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220473"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106974","DOI":"10.1016\/j.vph.2022.106974","article-title":"Beta-blockers in pulmonary arterial hypertension: Time for a second thought?","volume":"144","author":"Badagliacca","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2020.02.006","article-title":"TRPM4 modulates right ventricular remodeling under pressure load accompanied with decreased expression level","volume":"26","author":"Frede","year":"2020","journal-title":"J. Card. Fail."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.RES.0000085042.89656.C7","article-title":"Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat","volume":"93","author":"Hartmann","year":"2003","journal-title":"Circ. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00005344-200303000-00001","article-title":"Cardiac \u03b2-adrenoceptor changes in monocrotaline-treated rats: Differences between membrane preparations from whole ventricles and isolated ventricular cardiomyocytes","volume":"41","author":"Leineweber","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"173699","DOI":"10.1016\/j.ejphar.2020.173699","article-title":"The progression of pulmonary arterial hypertension induced by monocrotaline is characterized by lung nitrosative and oxidative stress, and impaired pulmonary artery reactivity","volume":"891","author":"Zimmer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cvr\/cvy076","article-title":"Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension","volume":"114","author":"Pimentel","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(90)90524-A","article-title":"Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension","volume":"176","author":"Wanstall","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/10641963.2012.721838","article-title":"Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension","volume":"35","author":"Sirmagul","year":"2013","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"L875","DOI":"10.1152\/ajplung.00293.2011","article-title":"Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension","volume":"302","author":"Christou","year":"2012","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.chest.2022.02.041","article-title":"BMI and treatment response in patients with pulmonary arterial hypertension: A meta-analysis","volume":"162","author":"McCarthy","year":"2022","journal-title":"Chest"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Oppegard, L.J., Barros, L.M., Pi, H., Kornfield, J., Hough, C.L., Rayner, S.G., Robinson, J.C., and Leary, P.J. (2023). Premorbid weight in pulmonary arterial hypertension. Pulm. Circ., 13.","DOI":"10.1002\/pul2.12308"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1248\/bpb.b13-00881","article-title":"Endothelin-1 receptors in rat tissues: Characterization by bosentan, ambrisentan and CI-1020","volume":"37","author":"Yokoyama","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","article-title":"Phosphodiesterase-5 inhibitors and the heart: Compound cardioprotection?","volume":"104","author":"Hutchings","year":"2018","journal-title":"Heart"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"L445","DOI":"10.1152\/ajplung.00450.2018","article-title":"Combination therapy improves vascular volume in female rats with pulmonary hypertension","volume":"317","author":"Lachant","year":"2019","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/HYPERTENSIONAHA.111.182261","article-title":"Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries","volume":"59","author":"Liang","year":"2012","journal-title":"Hypertension"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/bph.14172","article-title":"GPCRs in pulmonary arterial hypertension: Tipping the balance","volume":"175","author":"Iyinikkel","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"L401","DOI":"10.1152\/ajplung.00114.2010","article-title":"Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension","volume":"299","author":"Urboniene","year":"2010","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"P\u0119dzi\u0144ska-Betiuk, A., Gergs, U., Weresa, J., Remiszewski, P., Harasim-Symbor, E., and Malinowska, B. (2024). Comparison of cardioprotective potential of cannabidiol and \u03b2-adrenergic stimulation against hypoxia\/reoxygenation injury in rat atria and ventricular papillary muscles. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101379"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1242\/jeb.204.21.3765","article-title":"The energetics of rat papillary muscles undergoing realistic strain patterns","volume":"204","author":"Mellors","year":"2001","journal-title":"J. Exp. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Bankhead, P., Loughrey, M.B., Fernandez, J.A., Dombrowski, Y., McArt, D.G., Dunne, P.D., McQuaid, S., Gray, R.T., Murray, L.J., and Coleman, H.G. (2017). QuPath: Open source software for digital pathology image analysis. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-17204-5"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"658958","DOI":"10.4061\/2011\/658958","article-title":"Histologically measured cardiomyocyte hypertrophy correlates with body height as strongly as with body mass index","volume":"2011","author":"Tracy","year":"2011","journal-title":"Cardiol. Res. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"De Castro, A.L., Turck, P., Tavares, A.M.V., Gaspar, C.J., Bahr, A., Zimmer, A., Fernandes, T.R.G., Fernandes, R.O., Ortiz, V.D., and Tasca, S. (2025). Evaluation of the use of the myocardial performance index as a parameter of cardiac function in two experimental models of heart disease: Myocardial infarction and pulmonary hypertension. Pflugers Arch., ahead of print.","DOI":"10.1007\/s00424-025-03117-0"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8916\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:44:54Z","timestamp":1760035494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":76,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26188916"],"URL":"https:\/\/doi.org\/10.3390\/ijms26188916","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}